Targeting Neoantigens in Triple Negative Breast Cancer

针对三阴性乳腺癌的新抗原

基本信息

  • 批准号:
    10675496
  • 负责人:
  • 金额:
    $ 62.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Neoantigens have been identified by us and others as important targets of immunotherapy in the context of checkpoint blockade therapy, adoptive cell therapy, and vaccine therapy. We have recently initiated two phase 1 clinical trials of first generation neoantigen vaccines in breast cancer based on the neoantigen DNA vaccine and synthetic long peptide vaccine platforms. In preclinical models, we have optimized sequencing and epitope prediction algorithms for the identification and prioritization of neoantigens, and we have leveraged innovative technologies (CyTOF, single cell RNA sequencing) to comprehensively interrogate the immune response to neoantigen vaccination and other cancer immunotherapies. We propose to build on these observations by performing a randomized phase 1 trial of neoantigen DNA vaccine alone vs. neoantigen DNA vaccine plus anti-PD-L1, in patients with persistent triple negative breast cancer (TNBC) following neoadjuvant chemotherapy. The overall hypothesis is that enhancing neoantigen-specific T cell responses can improve clinical outcomes in TNBC. This hypothesis will be tested by completing the following aims: Specific Aim 1. Test the hypothesis that neoantigen vaccines +/- anti-PD-L1 can induce and/or enhance neoantigen-specific T cell responses. We have recently initiated a randomized phase 1 clinical trial of neoantigen DNA vaccines +/- anti-PD-L1 in TNBC patients with persistent disease following neoadjuvant chemotherapy. Next-generation sequencing and epitope prediction algorithms will be used to prioritize neoantigens. Neoantigen DNA vaccines will be designed and manufactured in the GMP facility at SCC. Specific Aim 2: Test the hypothesis that targeting tumor-associated macrophages (TAM) can enhance neoantigen-specific T cell responses in TNBC. Both embryonically-derived tissue-resident TAM and inflammatory monocyte-derived TAM restrain antitumor immunity in TNBC. We propose to combine CSF1/CSF1R blockade with CCR2 inhibition to simultaneously target both sources of TAM in the context of neoantigen vaccination in two mouse breast cancer models. The tumor microenvironment will be characterized by CyTOF and single cell RNA sequencing. Specific Aim 3: Test the hypothesis that a neoantigen simian Ad vector vaccine "prime" followed by a neoantigen DNA vaccine "boost" can enhance the response to breast cancer neoantigens. We propose a "prime/boost" strategy consisting of a simian recombinant Ad vaccine "prime," followed by a plasmid DNA vaccine "boost." This "prime/boost" neoantigen vaccine strategy represents a state-of-the-art vaccine strategy to more effectively induce antitumor immunity, and leverages expertise at WUSM within the fields of neoantigen DNA vaccines and recombinant Ad vector vaccines. Photocleavable tetramer analysis, CyTOF, and single cell RNA sequencing will be performed on neoantigen-specific T cells in the peripheral blood and the tumor microenvironment to rigorously evaluate the neoantigen-specific T cell response to vaccination.
项目概要/摘要 我们和其他人已将新抗原确定为免疫治疗的重要靶标 检查点阻断疗法、过继细胞疗法和疫苗疗法。我们最近启动了两个阶段 1 基于新抗原DNA疫苗的第一代乳腺癌新抗原疫苗的临床试验 和合成长肽疫苗平台。在临床前模型中,我们优化了测序和表位 用于新抗原的识别和优先排序的预测算法,我们利用了创新的 技术(CyTOF,单细胞 RNA 测序)全面询问免疫反应 新抗原疫苗接种和其他癌症免疫疗法。我们建议在这些观察的基础上 单独进行新抗原 DNA 疫苗与新抗原 DNA 疫苗加疫苗的随机 1 期试验 抗 PD-L1,用于新辅助治疗后持续性三阴性乳腺癌 (TNBC) 患者 化疗。总体假设是增强新抗原特异性 T 细胞反应可以改善 TNBC 的临床结果。该假设将通过完成以下目标来检验: 具体目标 1. 检验新抗原疫苗 +/- 抗 PD-L1 可以诱导和/或增强的假设 新抗原特异性 T 细胞反应。我们最近启动了一项随机 1 期临床试验 新抗原 DNA 疫苗 +/- 抗 PD-L1 用于新辅助治疗后疾病持续存在的 TNBC 患者 化疗。将使用下一代测序和表位预测算法来确定优先级 新抗原。新抗原 DNA 疫苗将在 SCC 的 GMP 设施中设计和制造。 具体目标 2:检验靶向肿瘤相关巨噬细胞 (TAM) 可以增强的假设 TNBC 中的新抗原特异性 T 细胞反应。胚胎来源的组织驻留 TAM 和 炎性单核细胞来源的 TAM 抑制 TNBC 的抗肿瘤免疫。我们建议结合 CSF1/CSF1R 阻断与 CCR2 抑制同时靶向 TAM 的两种来源 在两种小鼠乳腺癌模型中进行新抗原疫苗接种。肿瘤微环境将被表征 通过 CyTOF 和单细胞 RNA 测序。 具体目标 3:检验以下假设:新抗原猿猴 Ad 载体疫苗“引发”,然后是 新抗原DNA疫苗“加强”可以增强对乳腺癌新抗原的反应。我们建议 “初免/加强”策略,由猿猴重组 Ad 疫苗“初免”和随后的质粒 DNA 组成 疫苗“增强”。这种“初免/加强”新抗原疫苗策略代表了最先进的疫苗策略 更有效地诱导抗肿瘤免疫,并利用 WUSM 在以下领域的专业知识 新抗原DNA疫苗和重组Ad载体疫苗。光裂解四聚体分析,CyTOF, 并对外周血中的新抗原特异性 T 细胞进行单细胞 RNA 测序, 肿瘤微环境来严格评估新抗原特异性 T 细胞对疫苗接种的反应。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion.
  • DOI:
    10.1186/s12885-021-08239-z
  • 发表时间:
    2021-05-12
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Sankpal NV;Brown TC;Fleming TP;Herndon JM;Amaravati AA;Loynd AN;Gillanders WE
  • 通讯作者:
    Gillanders WE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William E. Gillanders其他文献

Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival
  • DOI:
    10.1186/s12885-025-14455-8
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    3.400
  • 作者:
    Priyanka S. Dhotare;Audrey C. Bochi-Layec;Timothy P. Fleming;William E. Gillanders;Ross M. Bremner;Kailas D. Sonawane;Narendra V. Sankpal
  • 通讯作者:
    Narendra V. Sankpal
Molecular characteristics of isthmus papillary thyroid cancers: Supporting evidence for unfavorable clinical behavior
  • DOI:
    10.1016/j.amjsurg.2023.09.005
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Eileen R. Smith;C. Corbin Frye;T.K. Pandian;William E. Gillanders;John A. Olson;Taylor C. Brown;Sina Jasim
  • 通讯作者:
    Sina Jasim
Micrometastatic Disease and Isolated Tumor Cells as a Predictor for Additional Breast Cancer Axillary Metastatic Burden
  • DOI:
    10.1245/s10434-010-1255-1
  • 发表时间:
    2010-09-19
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Amy Cyr;William E. Gillanders;Rebecca L. Aft;Timothy J. Eberlein;Feng Gao;Julie A. Margenthaler
  • 通讯作者:
    Julie A. Margenthaler
Predictors of Primary Breast Abscesses and Recurrence
  • DOI:
    10.1007/s00268-009-0170-8
  • 发表时间:
    2009-08-08
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Ankit Bharat;Feng Gao;Rebecca L. Aft;William E. Gillanders;Timothy J. Eberlein;Julie A. Margenthaler
  • 通讯作者:
    Julie A. Margenthaler
Best practices for bioinformatic characterization of neoantigens for clinical utility
  • DOI:
    10.1186/s13073-019-0666-2
  • 发表时间:
    2019-08-28
  • 期刊:
  • 影响因子:
    11.200
  • 作者:
    Megan M. Richters;Huiming Xia;Katie M. Campbell;William E. Gillanders;Obi L. Griffith;Malachi Griffith
  • 通讯作者:
    Malachi Griffith

William E. Gillanders的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William E. Gillanders', 18)}}的其他基金

Career Enhancement Program
职业提升计划
  • 批准号:
    10708580
  • 财政年份:
    2023
  • 资助金额:
    $ 62.51万
  • 项目类别:
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
  • 批准号:
    10904040
  • 财政年份:
    2023
  • 资助金额:
    $ 62.51万
  • 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
  • 批准号:
    9980320
  • 财政年份:
    2019
  • 资助金额:
    $ 62.51万
  • 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
  • 批准号:
    10458605
  • 财政年份:
    2019
  • 资助金额:
    $ 62.51万
  • 项目类别:
Targeting Neoantigens in Triple Negative Breast Cancer
针对三阴性乳腺癌的新抗原
  • 批准号:
    10224142
  • 财政年份:
    2019
  • 资助金额:
    $ 62.51万
  • 项目类别:
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
  • 批准号:
    10461044
  • 财政年份:
    2018
  • 资助金额:
    $ 62.51万
  • 项目类别:
Molecular, Cellular, and Tissue Characterization Unit
分子、细胞和组织表征单元
  • 批准号:
    10242184
  • 财政年份:
    2018
  • 资助金额:
    $ 62.51万
  • 项目类别:
Peripheral Blood Molecular Staging of Breast Cancer
乳腺癌的外周血分子分期
  • 批准号:
    7923851
  • 财政年份:
    2006
  • 资助金额:
    $ 62.51万
  • 项目类别:
Peripheral Blood Molecular Staging of Breast Cancer
乳腺癌的外周血分子分期
  • 批准号:
    7285941
  • 财政年份:
    2006
  • 资助金额:
    $ 62.51万
  • 项目类别:
Peripheral Blood Molecular Staging of Breast Cancer
乳腺癌的外周血分子分期
  • 批准号:
    7480253
  • 财政年份:
    2006
  • 资助金额:
    $ 62.51万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 62.51万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 62.51万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了